Pharma Fights Back: Six Lawsuits Say Stop

Eli Lilly did not send a cease-and-desist letter. It did not call a meeting. It did not negotiate. It filed six lawsuits — five of them in Texas — against companies it says are manufacturing and selling unapproved versions of retatrutide, its experimental GLP-1 weight-loss compound that has not yet cleared FDA approval for commercial distribution. When a pharmaceutical company with Lilly's legal budget decides the pre-litigation phase is already over, that tells you something. It tells you the behaviour was documented, the evidence was packaged, and someone made a deliberate decision that the message needed to arrive in a courtroom, not in an email.

I spent years before the suits around people who operated in grey markets. I understand the logic: if the product works, if the demand is real, and if the regulatory gap is wide enough to drive a truck through, someone will drive the truck. The GLP-1 boom created exactly that gap. Semaglutide compounding became a cottage industry almost overnight — pharmacies, clinics, and online operators selling versions of drugs the FDA had placed on shortage lists, legally protected under a compounding exemption that was always meant to be narrow. When the shortage list cleared, the legal cover evaporated. What remained was a market that had grown accustomed to operating in the grey and wasn't ready to stop.

Retatrutide is different in one important respect: it has not been approved at all. There is no shortage exemption. There is no compounding grey zone. Selling an unapproved version of retatrutide is not regulatory arbitrage — it is, on Lilly's argument, simply illegal. Kirkland & Ellis is not a firm you retain when you want to send a signal. It is a firm you retain when you want to win, and win expensively, and make the winning visible enough that everyone watching reconsiders their position.

What makes this story worth understanding — not just for Americans following pharma litigation, but for anyone operating in a regulated industry in Malta or across the EU — is the underlying legal architecture. The right to bring a lawsuit based on the distribution of an unapproved product does not require you to prove actual harm to a specific patient. It requires you to establish that the product exists, that it is being marketed, that it conflicts with your intellectual property or your regulatory position, and that the damage to your market is real or imminent. Lilly does not need a victim. It needs a judge to agree that the market is being distorted by actors who are not entitled to be in it. That is a much easier argument to make, and it is the argument that gets filed first.

The Depo-Provera litigation runs on an entirely different track but illuminates the same principle from the other direction. At a hearing held in late July, Pfizer's attorney Joseph Petrocinelli acknowledged that approximately 20 percent of the more than 6,200 cases filed in the Depo-Provera multidistrict litigation are ineligible for the settlement. That number — roughly 1,240 claimants — represents people who filed inside a mass tort structure and will not recover from it, either because their injuries fall outside the defined criteria, their exposure timelines don't fit the parameters, or their documentation is insufficient. Multidistrict litigation is a machine designed to resolve cases in volume. It is efficient for defendants and efficient for the plaintiffs' bar. It is not designed to be individually fair, and the 20 percent who fall outside it are learning that lesson in real time.

The practical lesson here sits at the intersection of both cases, and it applies whether you are a small business owner in Valletta, a freelancer working under an EU services contract, or an individual who signed up for a treatment that didn't go as promised. Every settlement structure has an eligibility map. Most people never ask to see it. They assume that if they were harmed, they qualify. They assume that if they joined the class, they are protected. They assume the lawyers working the case are working for them specifically. None of those assumptions are automatically true. The eligibility map is the most important document in any mass litigation, and it is almost never the document that gets attention until someone finds themselves on the wrong side of it.

Lilly's six lawsuits and Pfizer's 20 percent problem are not separate stories. They are the same story told from opposite ends of the pharmaceutical legal chain: one company using litigation as a market-clearing mechanism before regulators finish their work, and